References

Declining COVID-19 morbidity and case fatality in Germany: the pandemic end?

10.1007/s15010-022-01873-0 · 2022 · External reference

Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

10.1007/s15010-023-02169-7 · 2024 · External reference

COVID-19 outcomes in patients with hematologic malignancies in the era of COVID-19 vaccination and the Omicron variant

10.3390/cancers16020379 · 2024 · External reference

Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia

10.1200/jco.22.00088 · 2022 · External reference

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

10.1182/blood.2021011568 · 2021 · External reference

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

10.1182/bloodadvances.2021005094 · 2021 · External reference

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

10.1200/jco.1995.13.4.974 · 1995 · External reference

Long-term follow-up of patients with hairy cell leukemia after cladribine treatment

10.1182/blood.v92.6.1918 · 1998 · External reference

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia

10.1182/blood-2003-01-0014 · 2003 · External reference

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

10.1182/blood-2011-04-351502 · 2011 · External reference

Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia

10.1200/jco.19.02250 · 2020 · External reference

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

10.1056/nejm200107263450402 · 2001 · External reference

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal Phase 3 trial

10.1186/s13045-020-01004-y · 2021 · External reference

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

10.1182/blood.2020009688 · 2021 · External reference

Venetoclax in relapsed or refractory hairy-cell leukemia

10.1056/nejmc2216135 · 2023 · External reference

2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia

10.1182/blood.v83.10.2906.2906 · 1994 · External reference

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7- year follow-up

10.1038/sj.leu.2400513 · 1997 · External reference

Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia

10.1056/nejmoa1513257 · 2016 · External reference

Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia

10.1056/nejmoa1506583 · 2015 · External reference

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

10.1038/s41375-021-01210-8 · 2021 · External reference

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

10.1182/blood.2021013658 · 2023 · External reference

Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia

10.1056/nejmoa2031298 · 2021 · External reference

Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia

10.1056/evidoa2300074 · 2023 · External reference

BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2

10.1007/s00277-022-05026-z · 2023 · External reference

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

10.1182/blood-2011-09-379339 · 2012 · External reference

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

10.1182/blood-2009-01-201731 · 2009 · External reference

Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment

10.1016/j.ctrv.2010.05.003 · 2011 · External reference

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

10.1111/bjh.14129 · 2016 · External reference

Long term follow-up of a phase II study of cladribine with concurrent rituximab in patients with hairy cell leukemia variant

10.1182/bloodadvances.2021005039 · 2021 · External reference

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

10.1158/1078-0432.ccr-13-1848 · 2013 · External reference

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

10.1182/bloodadvances.2022007357 · 2022 · External reference

SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia

10.1111/bjh.18606 · 2023 · External reference

The course of patients with hairy cell leukemia during the omicron surge of the Covid-19 pandemic

10.1002/hon.3203 · 2023 · External reference

COVID-19 in patients with classic and variant hairy cell leukemia

10.1182/bloodadvances.2023011147 · 2023 · External reference

Differential expression of CD43, CD81 and CD200 in classic versus variant hairy cell leukemia

10.1002/cyto.b.21785 · 2019 · External reference

Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019

10.1093/infdis/jiaa273 · 2020 · External reference

Quantitative analysis of anti-N and anti-S antibody titers of SARS-CoV-2 infection after the third dose of COVID-19 vaccination

10.3390/vaccines10071143 · 2022 · External reference

Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL

10.1093/infdis/jiae106 · 2024 · External reference

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

10.1038/s41408-022-00776-5 · 2022 · External reference

Vaccinations in patients with chronic lymphocytic leukemia

10.1053/j.seminhematol.2024.01.003 · 2024 · External reference

T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine

2022 · External reference

Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2

10.1002/jha2.764 · 2023 · External reference

COVID-19 in a hairy cell leukemia patient: a rare case report

10.1620/tjem.2022.j058 · 2022 · External reference

Concurrent COVID-19 and pneumocystis carinii pneumonia in a patient subsequently found to have underlying hairy cell leukemia

10.1016/j.radcr.2022.06.026 · 2022 · External reference

A rare case of hairy cell leukemia with unusual loss of CD123 associated with COVID-19 at the time of presentation

10.1159/000512830 · 2020 · External reference

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

10.1158/1078-0432.ccr-13-1752 · 2013 · External reference

Hairy cell leukemia and COVID-19. Adaptation of treatment guidelines

10.1038/s41375-021-01257-7 · 2021 · External reference